신장암 환자에서 Pazopanib을 사용한 후 발생한 심부전 = Heart Failure Secondary to Pazopanib for Treatment of Metastatic Renal Cell Carcinoma

다국어 초록 (Multilingual Abstract)

A 78-year-old man was diagnosed with renal cell carcinoma, and left nephrectomy was performed. He started pazopanib. One month later, he visited our hospital because of general weakness and dyspnea. His oxygen saturation was low. A chest X-ray showed pulmonary edema and bilateral pleural effusion. An echocardiogram showed a larger left ventricle and lower ejection fraction than observed at the previous examination. The patient discontinued pazopanib and started diuretics and digoxin. His symptoms improved and a follow-up X-ray showed improvement in the pulmonary edema with bilateral pleural effusion. (Korean J Med 2016;90:330-333)

참고문헌 (Reference)

1 Hall PS, "The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients" 1 : 72-78, 2013

2 Lucarini V, "Pazopanib-induced heart failure in a metastatic sarcoma patient : between reversible side effect and efficacy" 2 : 59-65, 2014

3 A.-O. Abdallah, "Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report" SAGE Publications 22 (22): 561-565, 2016

4 Motzer RJ, "Pazopanib versus sunitinib in metastatic renal-cell carcinoma" 369 : 722-731, 2013

5 Sternberg CN, "Pazopanib in locally advanced or metastatic renal cell carcinoma : results of a randomized phase III trial" 28 : 1061-1068, 2010

6 Sanford M, "Pazopanib : in advanced renal cell carcinoma" 24 : 279-286, 2010

7 Qi WX, "Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors : a systematic review and meta-analysis of 36 clinical trials" 78 (78): 748-762, 2014

8 White AJ, "Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist" 131 : 92-94, 2009

9 Sternberg CN, "An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma" 87 : 342-350, 2014

10 Sternberg CN, "A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma : final overall survival results and safety update" 49 : 1287-1296, 2013